Science Corporation raised a Series D round backed by investors including Khosla Ventures, Tenet Healthcare, and Y Combinator. The company will use the proceeds to seek U.S. market entry for PRIMA, an implant and wearable device that restores partial sight to patients with advanced age-related macular degeneration. Additionally, the funding supports early clinical work on a bio-hybrid sensor combining silicon and cultured neurons. Working alongside Yale researchers, the startup intends to target conditions such as Parkinson's disease, brain injuries, and other neurological illnesses.
Key points
Science Corporation plans to introduce PRIMA to the United States via the FDA's Humanitar…: Science Corporation plans to introduce PRIMA to the United States via the FDA's Humanitarian Device Exemption pathway.
The startup is developing a bio-hybrid brain sensor composed of silicon and cultured neur…: The startup is developing a bio-hybrid brain sensor composed of silicon and cultured neurons to treat severe neurological conditions.
Initial early human neural trials are being designed in collaboration with Yale neurosurg…: Initial early human neural trials are being designed in collaboration with Yale neurosurgery professor Murat Günel.
Sources checked by our analysis pipeline: 1
Science Corporation, the medical technology start-up founded by former Neuralink president Max Hodak in 2021, raised a $400 million Series D, the company said in a blog post.
Investors in the new round valued the company at $3.5 billion, a person familiar with the deal told TechCrunch. Those backers included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.
Hodak, who talked his way into a graduate neuroscience lab as a college student and has pursued biotechnology ever since, co-founded Science to leverage new technologies to understand and interact with the brain.
Science’s first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, as well as being trialled for new conditions.
Hodak announced that the device is now being trialled for patients with another blindness-causing condition, Stargardt’s disease, while onstage at TechCrunch Disrupt.
With the funding, the company aims to bring the device to the United States through the FDA’s Humanitarian Device Exemption, which lets…
Built around an open-source architecture, Trmnl has launched a 31.5-inch color display designed to handle both dynamic household information and detailed artwork. The screen utilizes an advanced E Ink Spectra 6 panel supported by a specialized color conversion engine to render thousands of shades. Priced at $1,299, the limited initial production run aims to deliver long-lasting wall displays with minimal power consumption.
The substantial influx of capital positions the medical technology venture to advance specialized treatments for vision loss. Max Hodak established the firm to engineer advanced interventions, focusing primarily on resolving severe age-related visual impairment. This major valuation benchmark reflects strong investor commitment to developing transformative optical devices.
Recent technology disruptions were not caused by cyberattacks, according to a U.S. The official confirmed that the technical issues experienced were unrelated to any malicious cyber activity.